Category: Latest News

Shares of Mineralys Therapeutics Inc. (NASDAQ:MLYS) jumped 7.9% following the release of promising topline data from the company’s Phase 2 Explore-CKD study evaluating lorundrostat in patients with chronic kidney disease (CKD) and hypertension. The trial reached its primary endpoint, demonstrating a notable 7.5 mmHg reduction in systolic blood pressure compared to placebo — a result…

Shares of John Wiley & Sons, Inc. (NYSE: WLY) surged 8% in premarket trading on Tuesday after the academic publisher delivered stronger-than-expected fourth quarter earnings and offered encouraging guidance for the upcoming fiscal year. For the quarter ending April 30, Wiley posted adjusted earnings of $1.37 per share, beating the consensus estimate of $1.31. Quarterly…

Shares of Jabil Inc. (NYSE:JBL) gained 5.05% after the electronics manufacturing services provider posted third-quarter results that beat Wall Street expectations and boosted its full-year guidance. For the fiscal quarter ending May 31, Jabil reported adjusted earnings of $2.55 per share, ahead of analysts’ consensus of $2.29. Revenue rose to $7.8 billion, exceeding the $7.03…

Shares of Surgery Partners, Inc. (NASDAQ:SGRY) dropped 12% following the announcement that the company has wrapped up acquisition discussions with Bain Capital without reaching a deal. A Special Committee composed of independent board members reviewed Bain Capital’s non-binding offer to acquire the remaining shares it does not already own. After evaluation, the committee concluded that…

Shares of Immuneering Corporation (NASDAQ:IMRX) rose 7% on Monday following the release of encouraging interim results from a Phase 2a clinical trial evaluating its experimental cancer therapy, atebimetinib, in combination with modified gemcitabine/nab-paclitaxel (mGnP), as a first-line treatment for pancreatic cancer. The clinical-stage biotech reported that, six months into the study, 94% of patients were…

Shares of Dyne Therapeutics (NASDAQ:DYN) plunged 23% after the biotech firm announced changes to its regulatory strategy for DYNE-101, a treatment for myotonic dystrophy type 1 (DM1), following a recent Type C meeting with the U.S. Food and Drug Administration. Although the FDA granted Breakthrough Therapy Designation to DYNE-101—highlighting its potential to address serious unmet…

PureCycle Technologies (NASDAQ:PCT) saw its stock soar 12% after unveiling a major $300 million capital raise, signaling renewed investor confidence in the company’s long-term strategy to revolutionize plastic recycling and scale up its production capabilities. The funding, which combines contributions from both existing and new investors—including Duquesne Family Office LLC, Wasserstein Debt Opportunities, Samlyn Capital,…

Shares of Ventyx Biosciences (NASDAQ:VTYX) traded flat on Tuesday, even after the company released promising top-line results from a Phase 2a trial evaluating its investigational drug VTX3232 in patients with early-stage Parkinson’s disease. The biotech firm announced that the study successfully met its primary goal of establishing the drug’s safety and tolerability. Importantly, no treatment-emergent…

T-Mobile US (NASDAQ:TMUS) saw its shares drop by nearly 4.75% after Japan’s SoftBank Group (TYO: 9984) sold a significant portion of its holdings in the telecom giant. The move comes as the Tokyo-based conglomerate ramps up efforts to bankroll its growing ambitions in artificial intelligence. According to a Bloomberg report, SoftBank offloaded approximately 21.5 million…

U.S. stock futures edged lower on Tuesday as investors grew cautious amid escalating hostilities between Israel and Iran. While hopes for a ceasefire remain alive, behind-the-scenes talks reportedly continue, including possible discussions between American officials and Tehran. Meanwhile, President Donald Trump left the G7 summit in Canada earlier than expected, dismissing speculation that his departure…